We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

79 hedge funds and large institutions have $58.2M invested in Aclaris Therapeutics in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,100% more call options, than puts

Call options by funds: $112K | Put options by funds: $1K

85% more capital invested

Capital invested by funds: $31.4M → $58.2M (+$26.8M)

4.16% more ownership

Funds ownership: 70.29% → 74.45% (+4.2%)

8% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 26

2% less funds holding

Funds holding: 81 → 79 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

Holders
79
Holders Change
-2
Holders Change %
-2.47%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
24
Reduced
26
Closed
12
Calls
$112K
Puts
$1K
Net Calls
+$111K
Net Calls Change
+$156K

Top Buyers

Rank Fund Capital Flow
1
MP
MFN Partners
Massachusetts
+$4.14M
2
EC
EcoR1 Capital
California
+$3.46M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.35M
4
Morgan Stanley
Morgan Stanley
New York
+$1.31M
5
ECM
Endurant Capital Management
California
+$473K

Top Sellers

Rank Fund Capital Flow
1
Man Group
Man Group
United Kingdom
-$4.04M
2
RSCM
Rock Springs Capital Management
Maryland
-$2.28M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.05M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$884K
5
BlackRock
BlackRock
New York
-$650K
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
1
MFN Partners
Massachusetts
$7.56M +$4.14M +2,500,000 +167%
Renaissance Technologies
2
Renaissance Technologies
New York
$5.26M +$1.35M +813,581 +41%
BlackRock
3
BlackRock
New York
$4.99M -$650K -392,200 -13%
Morgan Stanley
4
Morgan Stanley
New York
$4.76M +$1.31M +790,841 +46%
EC
5
EcoR1 Capital
California
$3.94M +$3.46M +2,087,312 New
ECM
6
Endurant Capital Management
California
$3.88M +$473K +285,284 +16%
SI
7
Sofinnova Investments
California
$3.61M – – –
BC
8
Broadfin Capital
New York
$3.57M +$444K +268,039 +17%
RSCM
9
Rock Springs Capital Management
Maryland
$3.02M -$2.28M -1,374,754 -46%
Vanguard Group
10
Vanguard Group
Pennsylvania
$2.67M +$59.8K +36,090 +3%
Man Group
11
Man Group
United Kingdom
$2.45M -$4.04M -2,438,827 -65%
State Street
12
State Street
Massachusetts
$1.39M -$9.83K -5,932 -0.8%
Adage Capital Partners
13
Adage Capital Partners
Massachusetts
$1.32M – – –
ACM
14
Aisling Capital Management
New York
$1.2M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.1M +$149K +90,067 +18%
TI
16
Telemetry Investments
New York
$833K +$375K +226,407 +106%
Northern Trust
17
Northern Trust
Illinois
$650K -$57.1K -34,442 -9%
Millennium Management
18
Millennium Management
New York
$533K +$35.5K +21,397 +8%
PHP
19
Parkman Healthcare Partners
Connecticut
$425K +$373K +225,000 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$415K +$158K +95,527 +77%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$389K -$1.44K -870 -0.4%
JP Morgan Chase
22
JP Morgan Chase
New York
$388K -$17.9K -10,784 -5%
WG
23
Winton Group
United Kingdom
$381K -$14.3K -8,640 -4%
PPA
24
Parametric Portfolio Associates
Washington
$247K +$175K +105,349 +418%
AIM
25
Alambic Investment Management
California
$217K -$59K -35,600 -24%
1
2 3 4

ACRS Hedge Fund Activity: Q4 2019 in Review

79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2019, worth a combined $58.2M — up 85% from $31.4M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ACRS and 10 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 24 added.

The largest buyer was MFN Partners, adding an estimated $4.14M. The largest seller was Man Group, cutting an estimated $4.04M.

  • 79 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2019, down from 81 in Q3 2019.
  • Funds reported $58.2M of Aclaris Therapeutics stock for Q4 2019, up 85% quarter-over-quarter.
  • 10 funds opened new Aclaris Therapeutics positions in Q4 2019 and 12 closed out, a net change of -2 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2019 was MFN Partners, an estimated $4.14M added.
  • The largest Aclaris Therapeutics seller in Q4 2019 was Man Group, an estimated $4.04M sold.

Based on aggregated 13F filings for Q4 2019.